LSE - Delayed Quote CHF

Cosmo N.V. (0RGI.L)

56.50 -1.70 (-2.92%)

At close: November 6 at 3:06:20 PM GMT

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

TMX Newsfile 20d ago

CMHC.SW

CMOPF

0RGI.L
-2.92%
Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

TMX Newsfile 1mo ago

C43.F

CMHC.SW

CMOPF
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

TMX Newsfile 3mo ago

C43.F

CMOPF

0RGI.L
-2.92%
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026

TMX Newsfile 4mo ago

0RGI.L
-2.92%
C43.F

CMOPF
Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany

TMX Newsfile 4mo ago

CMOPF

0RGI.L
-2.92%
C43.F
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

TMX Newsfile 4mo ago

GLENMARK.NS

CMOPF

0RGI.L
-2.92%
Cosmo Announces SIX Ticker Symbol Change to "CMHC"

TMX Newsfile 2mo ago

COPN.SW

0RGI.L
-2.92%
C43.F
UPDATE: Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

GlobeNewswire 2mo ago

COPN.SW
Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

GlobeNewswire 2mo ago

COPN.SW
Cosmo NV (CMOPF) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com 3mo ago
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant

TMX Newsfile 6mo ago

COPN.SW

CMOPF
Voting Results of Cosmo's 2026 AGM

TMX Newsfile 6mo ago

COPN.SW

CMOPF

U.S. markets closed

Cosmo N.V. (0RGI.L)

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026

Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany

Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

Cosmo Announces SIX Ticker Symbol Change to "CMHC"

UPDATE: Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Cosmo NV (CMOPF) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant

Voting Results of Cosmo's 2026 AGM